Group A
Compensated, no portal hypertension
No varices, no CSPH, no prior decompensation events.
- Annual mortality risk
- ~6%
- 5-year risk of dying on waitlist
- ~27%
Understanding your risk
A low MELD score does not always mean low risk.
MELD is a useful number. It is not the whole story of your liver disease. If you have been told your MELD is “not high enough yet” and sent home to wait, this page is for you.
Not medical advice. Clinical decisions remain with your transplant team.
What MELD measures, and what it doesn’t
The MELD score (Model for End-Stage Liver Disease) is a lab-based number built from three blood tests: bilirubin, creatinine, and INR (with sodium added in MELD-Na and MELD 3.0). It is used by transplant centers and the national allocation system to rank patients by urgency.
That is what MELD does well: it measures how sick your liver chemistry looks on the day of the blood draw.
Many of the complications that actually kill people on the liver transplant waiting list do not move MELD very much, or do not move it in time.
What MELD doesn’t count
- Varices — enlarged veins in the esophagus or stomach that can bleed suddenly.
- Portal hypertension / clinically significant portal hypertension (CSPH) — high pressure in the portal vein system, which drives many of the dangerous complications of cirrhosis.
- Splenomegaly — an enlarged spleen, a downstream sign of portal hypertension.
- Ascites — fluid buildup in the abdomen, especially when it needs drainage.
- Hepatic encephalopathy — confusion or altered mental status from the liver’s inability to clear toxins.
- Multiple decompensation events — more than one serious episode (for example, a variceal bleed plus ascites, or repeated encephalopathy).
Any one of these changes your real-world risk, even when the lab number looks “okay.”
Your real risk depends on your clinical picture
Here’s how annual mortality actually breaks out for liver patients with MELD scores under 16, based on clinical stage — not just the lab number. These numbers are drawn from published cirrhosis staging literature.
Group B
Portal hypertension, no major events yet
Varices and/or CSPH present, but no ascites, variceal bleed, or hepatic encephalopathy yet.
- Annual mortality risk
- ~9%
- 5-year risk of dying on waitlist
- ~38%
Group C
One serious decompensation event
Has had one of: ascites requiring drainage, variceal bleed, or a hepatic encephalopathy episode.
- Annual mortality risk
- ~15%
- 5-year risk of dying on waitlist
- ~56%
Group D
Multiple decompensations, severe CSPH
Two or more serious events (for example, ascites plus variceal bleed, or recurrent hepatic encephalopathy). Significant spleen involvement and severe portal hypertension.
- Annual mortality risk
- ~30%
- 5-year risk of dying on waitlist
- >80%
Risk estimates are based on published cirrhosis staging literature and actuarial data. Individual outcomes vary. This is not a substitute for evaluation by a transplant hepatologist.
What this means if you’re waiting
If you look at the cards above and your clinical picture lines up with Group C or Group D — a serious decompensation event, or more than one — then a “low” MELD score can be genuinely misleading. Your lab number may be under 16 while your real mortality risk on the waiting list is much higher than that number suggests.
If you are in Group C or D and your transplant center has not had this specific conversation with you — or if you have been removed from the waitlist for reasons you do not fully understand — you have options. Getting a second evaluation from another transplant center is not disloyalty. It is allowed, it is common, and for some patients it is the most important single step they take.
A second evaluation is a clinical second opinion. It does not end your relationship with your current team. It simply puts another set of expert eyes on your case.